Plain-English translation of NCT07276282 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help prevent future heart problems in people who have recently had a heart attack. The medication works by reducing inflammation in your arteries, which scientists believe plays a major role in plaque buildup and heart disease. Half of the participants will receive the medication as a monthly injection, while the other half will receive a placebo (inactive injection).
Even with today's best heart medications and treatments, many heart attack survivors experience another heart attack or need to return to the hospital within a year. Doctors believe inflammation in the arteries is a major cause of this continued risk that current treatments don't fully address, so this trial is testing whether reducing inflammation with this medication could help prevent these serious outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive monthly injections of either the study medication or placebo under the skin for the duration of the trial. During your participation, you will also have specialized heart imaging tests (ultrasound, optical coherence tomography, and near-infrared spectroscopy) performed through catheters to directly visualize how the plaque in your arteries is changing over time. The trial involves multiple visits to monitor your heart health and collect detailed images to measure whether the medication is slowing or stabilizing the buildup in your coronary arteries.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Switzerland